Conclusions
Faropenem, a stable and orally bioavailable β-lactam, has broad-spectrum
in vitro antimicrobial activity against many Gram-positive and
Gram-negative aerobes and anaerobes and is resistant to hydrolysis by
nearly all β-lactamases. A 7-day regimen of faropenem is effective in
the treatment of uncomplicated cystitis. Faropenem is a potential
solution to combat the emergence of resistance among respiratory tract
pathogens. It is an alternative to fluoroquinolones or
macrolides/ketolides when there is a concern with resistant pathogens.